These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 19900861

  • 21. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.
    Cancer; 2010 Jun 15; 116(12):3025-33. PubMed ID: 20564408
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
    Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.
    Lung Cancer; 2009 May 15; 64(2):199-206. PubMed ID: 18951651
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
    Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6049-55. PubMed ID: 17062680
    [Abstract] [Full Text] [Related]

  • 27. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R.
    Lung Cancer; 2011 Apr 15; 72(1):84-91. PubMed ID: 20705357
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
    Merimsky O, Cheng CK, Au JS, von Pawel J, Reck M.
    Oncol Rep; 2012 Aug 15; 28(2):721-7. PubMed ID: 22614912
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB, NCIC Clinical Trials Group Working Group on Economic Analysis.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):298-306. PubMed ID: 20160168
    [Abstract] [Full Text] [Related]

  • 34. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
    Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ.
    Oncology; 2010 Mar 03; 79(1-2):78-84. PubMed ID: 21071994
    [Abstract] [Full Text] [Related]

  • 35. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer.
    Murillo JR, Koeller J.
    Oncologist; 2006 Mar 03; 11(10):1095-9. PubMed ID: 17110629
    [Abstract] [Full Text] [Related]

  • 36. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    J Clin Oncol; 2006 Aug 20; 24(24):3831-7. PubMed ID: 16921034
    [Abstract] [Full Text] [Related]

  • 37. Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
    Vergnenègre A, Monnet I, Chouaïd C, Hureaux J, Mazières J, Quéré G, Lombard JN, Cumin I, Abdiche S, Ejnaini CN, Bonnabau H, Decroisette Ch, GFPC team.
    Lung Cancer; 2011 Nov 20; 74(2):264-7. PubMed ID: 21571389
    [Abstract] [Full Text] [Related]

  • 38. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
    Böker B, Lüders H, Grohé C.
    Pneumologie; 2012 Feb 20; 66(2):89-95. PubMed ID: 22337328
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].
    Duchnowska R, Siemiatkowska A, Grala B, Smoter M.
    Pneumonol Alergol Pol; 2008 Feb 20; 76(6):451-5. PubMed ID: 19173195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.